IBDEI0QT ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12576,1,2,0)
 ;;=2^TB
 ;;^UTILITY(U,$J,358.3,12576,1,3,0)
 ;;=3^86580
 ;;^UTILITY(U,$J,358.3,12577,0)
 ;;=95024^^52^574^3^^^^1
 ;;^UTILITY(U,$J,358.3,12577,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12577,1,2,0)
 ;;=2^INTRADERMALS (EACH)
 ;;^UTILITY(U,$J,358.3,12577,1,3,0)
 ;;=3^95024
 ;;^UTILITY(U,$J,358.3,12578,0)
 ;;=86510^^52^574^2^^^^1
 ;;^UTILITY(U,$J,358.3,12578,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12578,1,2,0)
 ;;=2^HISTOPLASMOSIS
 ;;^UTILITY(U,$J,358.3,12578,1,3,0)
 ;;=3^86510
 ;;^UTILITY(U,$J,358.3,12579,0)
 ;;=99395^^52^575^1^^^^1
 ;;^UTILITY(U,$J,358.3,12579,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12579,1,2,0)
 ;;=2^PREVENTIVE MED,EST PT 18-39
 ;;^UTILITY(U,$J,358.3,12579,1,3,0)
 ;;=3^99395
 ;;^UTILITY(U,$J,358.3,12580,0)
 ;;=99396^^52^575^2^^^^1
 ;;^UTILITY(U,$J,358.3,12580,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12580,1,2,0)
 ;;=2^PREVENTIVE MED,EST PT 40-64
 ;;^UTILITY(U,$J,358.3,12580,1,3,0)
 ;;=3^99396
 ;;^UTILITY(U,$J,358.3,12581,0)
 ;;=99397^^52^575^3^^^^1
 ;;^UTILITY(U,$J,358.3,12581,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12581,1,2,0)
 ;;=2^PREVENTIVE MED,EST PT > 64
 ;;^UTILITY(U,$J,358.3,12581,1,3,0)
 ;;=3^99397
 ;;^UTILITY(U,$J,358.3,12582,0)
 ;;=99385^^52^576^1^^^^1
 ;;^UTILITY(U,$J,358.3,12582,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12582,1,2,0)
 ;;=2^PREVENTIVE MED,NEW PT 18-39
 ;;^UTILITY(U,$J,358.3,12582,1,3,0)
 ;;=3^99385
 ;;^UTILITY(U,$J,358.3,12583,0)
 ;;=99386^^52^576^2^^^^1
 ;;^UTILITY(U,$J,358.3,12583,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12583,1,2,0)
 ;;=2^PREVENTIVE MED,NEW PT 40-64
 ;;^UTILITY(U,$J,358.3,12583,1,3,0)
 ;;=3^99386
 ;;^UTILITY(U,$J,358.3,12584,0)
 ;;=99387^^52^576^3^^^^1
 ;;^UTILITY(U,$J,358.3,12584,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12584,1,2,0)
 ;;=2^PREVENTIVE MED,NEW PT > 64
 ;;^UTILITY(U,$J,358.3,12584,1,3,0)
 ;;=3^99387
 ;;^UTILITY(U,$J,358.3,12585,0)
 ;;=B18.2^^53^577^26
 ;;^UTILITY(U,$J,358.3,12585,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12585,1,3,0)
 ;;=3^Hepatitis C,Chr
 ;;^UTILITY(U,$J,358.3,12585,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,12585,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,12586,0)
 ;;=C44.99^^53^577^50
 ;;^UTILITY(U,$J,358.3,12586,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12586,1,3,0)
 ;;=3^Skin Cancer,Unspec
 ;;^UTILITY(U,$J,358.3,12586,1,4,0)
 ;;=4^C44.99
 ;;^UTILITY(U,$J,358.3,12586,2)
 ;;=^5001094
 ;;^UTILITY(U,$J,358.3,12587,0)
 ;;=E11.9^^53^577^15
 ;;^UTILITY(U,$J,358.3,12587,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12587,1,3,0)
 ;;=3^Diabetes Type 2
 ;;^UTILITY(U,$J,358.3,12587,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,12587,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,12588,0)
 ;;=E11.40^^53^577^16
 ;;^UTILITY(U,$J,358.3,12588,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12588,1,3,0)
 ;;=3^Diabetes Type 2 w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,12588,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,12588,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,12589,0)
 ;;=E78.2^^53^577^27
 ;;^UTILITY(U,$J,358.3,12589,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12589,1,3,0)
 ;;=3^Hyperlipidemia,Mixed
 ;;^UTILITY(U,$J,358.3,12589,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,12589,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,12590,0)
 ;;=E78.5^^53^577^28
 ;;^UTILITY(U,$J,358.3,12590,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12590,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,12590,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,12590,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,12591,0)
 ;;=E66.3^^53^577^44
 ;;^UTILITY(U,$J,358.3,12591,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12591,1,3,0)
 ;;=3^Overweight
